GlassScriptPhysician profile
Kelly M Watson
NPI 1154711265
$2,527.26
in general payments reported to CMS, 2019-2025
24 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $491 · 2023: $626 · 2024: $800 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $616.25 | 2023-2025 | |
| Braeburn INC. | $290.88 | 2023-2025 | Brixadi |
| Abbott Laboratories | $281.46 | 2022-2025 | Freestyle Libre |
| Lilly USA, LLC | $212.34 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Alkermes, INC. | $156.91 | 2022-2024 | Aristada, Vivitrol, Lybalvi |
| Novo Nordisk INC | $132.12 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Indivior INC. | $127.14 | 2021-2023 | Sublocade |
| Amgen INC. | $120.83 | 2021-2023 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.51 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $72.43 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.67 | 2021-2023 | Xifaxan |
| Gilead Sciences, INC. | $48.78 | 2021 | |
| Eisai INC. | $46.10 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $41.68 | 2022-2023 | Abilify Maintena, Rexulti |
| Dexcom, INC. | $40.07 | 2021-2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $34.14 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $30.59 | 2024-2025 | Uzedy |
| Pfizer INC. | $24.00 | 2024 | |
| Jazz Pharmaceuticals INC. | $21.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.47 | 2022 | |
| Glaxosmithkline, LLC. | $14.06 | 2025 | Bexsero |
| Collegium Pharmaceutical, INC. | $13.54 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.94 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $12.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.